Hyperlipoproteinemia Type III: Clinical Trials

2 trials for Hyperlipoproteinemia Type III, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Terminated 1

Follow Hyperlipoproteinemia Type III: new trials by email Literature Review of Hyperlipoproteinemia Type III trials Research Report on Hyperlipoproteinemia Type III

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
torcetrapib/atorvastatin, atorvastatin, fenofibrate - Hyperlipoproteinemia Type III
Phase 3TerminatedPfizer412005-03-012012-02-17
Type III Dysbetalipoproteinemia
Rosuvastatin, rosuvastatin, pravastatin - Hyperlipoproteinemia Type III
Phase 3CompletedAstraZeneca302005-02-012010-11-19

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Dyslipidemias (2)  ·  Genetic Diseases, Inborn (2)  ·  Hyperlipidemias (2)  ·  Hyperlipoproteinemias (2)  ·  Lipid Metabolism Disorders (2)  ·  Lipid Metabolism, Inborn Errors (2)  ·  Metabolic Diseases (2)  ·  Metabolism, Inborn Errors (2)  ·  Nutritional and Metabolic Diseases (2)

Interventions

Atorvastatin (1)  ·  Fenofibrate (1)  ·  Pravastatin (1)  ·  Rosuvastatin Calcium (1)  ·  torcetrapib (1)

Sponsors

AstraZeneca (1)  ·  Pfizer (1)

Countries

Canada (1)  ·  Norway (1)  ·  South Africa (1)  ·  United States (1)